S. 3788 · 119th Congress (2025–2027)
CLEAR LABELS Act
This bill requires drugs and active pharmaceutical ingredients made available in the U.S. market to be labeled with the names and locations of their manufacturers.
Specifically, a finished, packaged drug product must be labeled with the name and place of business of (1) the original manufacturer (or manufacturers) of each active pharmaceutical ingredient; (2) the original manufacturer of the finished drug product; and (3) the packer or distributor, if any. This information must be printed on the product label or made available electronically. Active pharmaceutical ingredients (which are generally sold to manufacturers and researchers, not consumers) must also be labeled with the name and place of business of their original manufacturers.
Under the bill, the original manufacturer is the establishment that conducts the majority of the significant phases of manufacturing to produce the ingredient or product.
The Food and Drug Administration (FDA) has discretion to determine whether a violation of these requirements constitutes misbranding and to assess a civil fine. The FDA must consider certain factors in determining whether to assess a fine, including whether the violator was notified of their noncompliance and was provided an opportunity to correct the violation.
Finally, the FDA must coordinate with U.S. Customs and Border Protection to address any overlap between these requirements and existing requirements for imported drugs.
These provisions take effect five years after the bill is enacted.
Show official title
A bill to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information.
Reported
This bill’s path
This is S. 3788’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
- Sponsor
- Sen. Rick Scott (R-FL)
- Cosponsors
12 cosponsors
4 original · 8 later
11 R · 1 D
- Sen. Katie Boyd Britt (R-AL)· Original · Feb 5, 2026
- Sen. Kirsten E. Gillibrand (D-NY)· Original · Feb 5, 2026
- Sen. Ron Johnson (R-WI)· Original · Feb 5, 2026
- Sen. Tommy Tuberville (R-AL)· Original · Feb 5, 2026
- Sen. Ashley Moody (R-FL)· Later · Feb 12, 2026
- Sen. Mike Lee (R-UT)· Later · Mar 9, 2026
- Sen. Kevin Cramer (R-ND)· Later · Mar 11, 2026
- Sen. James E. Risch (R-ID)· Later · Mar 23, 2026
- Sen. Chuck Grassley (R-IA)· Later · Mar 25, 2026
- Sen. Pete Ricketts (R-NE)· Later · Mar 25, 2026
- Sen. Joni Ernst (R-IA)· Later · Apr 13, 2026
- Sen. Alan Armstrong (R-OK)· Later · Jul 13, 2026
- Policy area
- Health
- Subjects
- Consumer affairs
- Manufacturing
- Prescription drugs
- Supply chain
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
▸ 3 committee actions · Feb 5, 2026 – Jul 27, 2026
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sources
- Congress.gov action
- Senate
Ordered reported
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Sources
- Congress.gov action
- Senate
Reported by committee
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
Sources
- Congress.gov action
- Senate
Committees
- SenateHealth, Education, Labor, and PensionsReferred Feb 5, 2026 · Hearings by (full committee) Mar 19, 2026 · Markup Jul 22, 2026 · Reported Jul 27, 2026
Jul 22, 2026 · Open business meeting
Mar 19, 2026 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (3)
CLEAR LABELS Act
Short title, Display title · Reported to Senate, Introduced in Senate
Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act
Short title · Reported to Senate, Introduced in Senate
A bill to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information.
Official title · Introduced in Senate